Monopar Therapeutics Reports Q1 2026 Results and Wilson Disease Program Progress

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company headquartered in Wilmette, Illinois, released its financial results for the first quarter of 2026 on May 14. Alongside the financial report, the company provided significant updates regarding its clinical pipeline and ongoing efforts to address unmet medical needs through innovative therapeutic developments. The company is currently listed on the Nasdaq under the ticker symbol MNPR.^[1][2][3]

A major focus of the business update was the development of ALXN1840, also known as tiomolibdate choline (TMC), which is being developed for the treatment of Wilson disease. Monopar reported that it remains on schedule to submit a New Drug Application (NDA) for the treatment in mid-2026. This timeline follows recent clinical milestones, including the presentation of data from the randomized controlled Phase 3 FoCus trial.^[1][3]

In April 2026, Monopar shared new analyses from the Phase 3 FoCus trial at the American Academy of Neurology (AAN) Annual Meeting. The presentation, which included both oral and poster formats, detailed findings regarding the clinical benefit of tiomolibdate choline compared to the current standard-of-care for patients suffering from neurologic Wilson disease. These results were presented as part of a late-breaker session at the conference.^[1][3]